For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with low PSA levels prior to postprostatectomy radiotherapy who received either short-term or long-term hormone therapy with radiotherapy derived no survival advantage over postprostatectomy radiotherapy alone. Those with higher pre-radiotherapy PSA levels did see some benefit, however, suggesting that adding hormones in this group might be worthwhile.
New AACR President-Elect and Board Members Announced
The members of the American Association for Cancer Research (AACR) have elected Robert H. Vonderheide, MD, DPhil, as the AACR President-elect for 2026–2027. Dr. Vonderheide will become President-Elect on Monday, April 20, during AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2026 in San Diego. He will assume the Presidency in April 2027 at the AACR Annual Meeting in Orlando.
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges.
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response (pCR) from no pCR, but did provide important prognostic information.
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New York Times, opened to the science section, and read aloud: “Cancer Researcher in South Africa Who Falsified Data Is Fired.”
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY JOHNSON & JOHNSON
Evolving Treatment Landscape in First-Line EGFR-Mutant NSCLC: New Insights Into Combination Therapies
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
James P. Allison, PhD, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to James P. Allison, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2026, to be held April 17-22 in San Diego. James P. Allison, PhD Dr. Allison is...
POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings
Syed Ali Abutalib, MD Angela Dispenzieri, MD POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monoclonal plasma cell dyscrasia, and skin...
Integrative Oncology Scholars Program
Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/view/integrative-oncology-scholars-/home). Now in its sixth year, the Integrative Oncology Scholars...
Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients
In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. Study Details The study included data from 14,765 individuals with cancer entered into the 100,000 Genomes...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
Electroacupuncture Relieves Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study
Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer...
